- Home
- / Nkarta Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Nkarta Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.4
2024-10-29
Market Capitalization
$240.6 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|
| General and administrative expense | 15.3M | 23.0M | 28.1M | 34.9M | 31.5M | 31.6M |
| Operating expense total | 51.5M | 86.4M | 119.0M | 128.2M | 122.0M | |
| EBIT | (51.5M) | (86.4M) | (119.0M) | (131.6M) | (128.2M) | (122.0M) |
| Investment income | 313.0K | 370.0K | 5.6M | 14.1M | 19.3M | 15.5M |
| Net Income | (91.4M) | (86.1M) | (113.8M) | (117.5M) | (108.8M) | (104.1M) |
| EPS | (2.6) | (2.0) | (1.6) | (1.4) |